Coherus Oncology (CHRS) Net Income towards Common Stockholders (2013 - 2026)

Coherus Oncology has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting -$1.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$1.4 million, up 84.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $358.9 million (up 452.16% YoY), and the FY2025 annual result was $351.1 million, up 43.97% from the prior year.
• Net Income towards Common Stockholders came in at -$1.4 million for Q1 2026 at Coherus Oncology, down from $8.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $342.6 million in Q2 2025 to a low of -$96.1 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is -$9.2 million (2025), against an average of $3.8 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 124.9% in 2022 and jumped 717.15% in 2025, its largest moves.
• Coherus Oncology's Net Income towards Common Stockholders stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then jumped by 94.22% to -$4.6 million in 2024, then jumped by 289.09% to $8.7 million in 2025, then sank by 115.99% to -$1.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.4 million (Q1 2026), $8.7 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.